Human integrin αvβ5: Homology modeling and ligand binding

Journal of Medicinal Chemistry

Volumn 47, Issue 17, 2004, Pages 4166-4177

  Marinelli, Luciana ^c   Gottschalk, Kay E ^b   Meyer, Axel ^a   Novellino, Ettore ^c   Kessler, Horst ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA5 INTEGRIN; ALPHAVBETA5 INTEGRIN; ARGINYLGLYCYLASPARTIC ACID; BETA5 INTEGRIN; CARBOXYLIC ACID; CILENGITIDE; INTEGRIN RECEPTOR; LIGAND; LYSINE; SOLVENT; TYROSINE; UNCLASSIFIED DRUG; INTEGRIN; VITRONECTIN RECEPTOR;

ARTICLE; BINDING SITE; CRYSTAL STRUCTURE; ENERGY; HUMAN; LIGAND BINDING; MOLECULAR DYNAMICS; MOLECULAR MODEL; MUTAGENESIS; PROTEIN CONFORMATION; SEQUENCE HOMOLOGY; SIMULATION; AMINO ACID SEQUENCE; CHEMICAL STRUCTURE; CHEMISTRY; MOLECULAR GENETICS; PROTEIN BINDING;

AMINO ACID SEQUENCE; HUMANS; INTEGRIN ALPHAVBETA3; INTEGRINS; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; PROTEIN BINDING; RECEPTORS, VITRONECTIN; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 3843120058     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030635j     Document Type: Article

References (85)

1. (a) Brower, V. Tumor angiogenesis - new drugs on the block. Nat. Biotechnol. 1999, 17, 963-968.
2. (b) Carmeliet, P.; Jain, R. K. Angiogenesis in Cancer and other Disease. Nature 2000, 407, 249-257.
3. (c) Jain, R. K. Molecular regulation of vessel maturation. Nat. Med. 2003, 9, 685-693.
4. (d) Marx, J. A Boost for Tumor Starvation. Science 2003, 301, 452-453.
5. (a) Hynes, R. O. Integrins: Versatility, Modulation, and Signaling in Cell Adhesion. Cell 1992, 69, 11-25.
6. (b) Hynes, R. O.; Bader, B. L.; Hodivala-Dilke, K. Integrins in Vascular Development. Braz. J. Med. Biol. Res. 1999, 32, 501-510.
7. (c) Ruegg, C.; Dormond, O.; Foletti, A. Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target? Endothelium 2002, 9, 151-160.
8. (d) Kim, S.; Bakre, M.; Yin, H.; Varner, J. A. Inhibition of endothelial cell survival and angiogenesis by protein kinase A. J. Clin. Invest. 2002, 110, 933-941.
9. (e) Hynes, R. O. A reevaluation of integrins as regulators of angiogenesis. Nature Medicine 2002, 8, 918-921.
10. (f) Mousa, S. A. Anti-integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications. Curr. Opin. Chem. Biol. 2002, 6, 534-541
11. (a) Brooks, P. C.; Clark, R. A.; Cheresh, D. A. Requirement of Vascular integrin αvβ3 for angiogenesis. Science 1994, 264, 569-571.
12. (b) Eliceiri, B. P.; Cheresh, D. A. Role of alpha v integrins during angiogenesis. Cancer J. 2000, 13, 245-249.
13. Dechantsreiter, M. A.; Planker, E.; Mathä, B.; Lohof, E.; Hölzemann, G.; Jonczyk, A.; Goodman, S. L.; Kessler, H. N-Methylated Cyclic RGD Peptides as Highly Active and Selective αvβ3 Integrin Antagonists. J. Med. Chem. 1999, 42, 3033-3040.
14. Burke, P. A.; DeNardo, S. J.; Miers, L. A.; Lamborn, K. R.; Matzku, S.; DeNardo, G. L. Cilengitide Targeting of avb3 Integrin Receptor Synergizes with Radioimmunotherapy to Increase Efficacy and Apoptosis in Breast Cancer Xenografts. Cancer Res. 2002, 62, 4263-4272.
15. (a) Smith, J. W.; Vesta, D. J.; Irwin, S. V.; Burke, T. A.; Cheresh, D. A. Purification and functional characterization of integrin alpha v beta 5. An adhesion receptor for vitronectin. J. Biol. Chem. 1990, 265, 11008-11013.
16. (b) Friedlander, M.; Theesfeld, C. L.; Sugita, M.; Fruttinger, M.; Thomas, M. A.; Chang, S.; Cheresh, D. A. Involvement of Integrins αvβ3 and αvβ5 in Ocular Neovascular diseases. Proc. Natl. Acad. Sci. 1996, 93, 9764-9769.
17. Friedlander, M.; Brooks, P. C.; Shaffer, R. W.; Kincaid, C. M.; Varner, J. A.; Cheresh, D. A. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995, 270, 1500-2.
18. (a) Bader, B. L.; Rayburn, H.; Crowley, D.; Hynes, R. O. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell 1998, 95, 507-519.
19. 3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J. Clin. Invest. 1999, 103, 229-238.
20. Kumar, C. C.; Malkowski, M.; Yin, Z.; Tanghetti, E.; Yaremko, B.; Nechuta, T.; Varner, J.; Liu, M.; Smith, E. M.; Neustadt, B.; Presta, M.; Armstrong, L. Inhibition of angiogenesis and tumor growth by SCH221153, a dual (αvβ3 and αvβ5 integrin receptor antagonist. Cancer Res. 2001, 61, 2232-2238.
21. (a) Humphries, M. J. Integrin structure. Biochem. Soc. Trans. 2000, 28, 311-339.
22. (b) Hynes, R. O. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110, 673-687.
23. (a) Ruoslahti, E.; Pierschbacher, M. D. New perspectives in cell adhesion: RGD and integrins. Science 1987, 238, 491-497.
24. (b) D'Souza, S. E.; Ginsberg, M. H.; Plow, E. F. Arginyl-Glycyl-Aspartic acid (RGD) a cell adhesion motif. Trends Biochem. Sci. 1991, 16, 246-250.
25. (a) Aumailley, M.; Gurrath, M.; Müller, G.; Calvete, J.; Timpl, R.; Kessler, H. Arg-Gly-Asp constrained within cyclic penta-peptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett. 1991, 291, 50-54.
26. (b) Müller, G.; Gurrath, M.; Kessler, H.; Timpl, R. Dynamic Forcing, a Method for Evaluating Activity and Selectivity Profiles of RGD (Arg-Gly-Asp) Peptides. Angew. Chem., Int. Ed. Engl. 1992, 31, 326-328.
27. (c) Gurrath, M.; Müller, G.; Kessler, H.; Aumailley, M.; Timpl, R. Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides, Eur. J. Biochem. 1992, 210, 911-921.
28. (d) Peishoff, C. E.; Ali, F. E.; Bean, J. W.; Calvo, R.; D'Ambrosio, C. A.; Eggleston, D. S.; Hwang, S. M.; Kline, T. P.; Koster, P. F.; Nichols, A.; Powers, D.; Romoff, T.; Samanen, J. M.; Stadel, J.; Vasko, J.; Kopple, K. D. Investigation of conformational specificity at GPIIb/IIIa: evaluation of conformationally constrained RGD peptides. J. Med. Chem. 1992, 35, 3962-3969.
29. (e) Pfaff, M.; Tangemann, K.; Müller, B.; Gurrath, M.; Müller, G.; Kessler, H.; Timpl, R.; Engel, J. Selective recognition of cyclic RGD peptides of NMR defined conformation by αIIbβ3, αvβ3 and α5β1 integrins. J. Biol. Chem. 1994, 269, 20233-20238.
30. (f) Müller, G.; Gurrath, M.; Kessler, H. Pharmacophore refinement of gpIIb/IIa antagonists based on comparitive studies of antiadhesive cyclic and acyclic RGD peptides. J. Comput.-Aided Mol. Des. 1994, 8, 709-730.
31. (g) Haubner, R.; Finsinger, D.; Kessler, H. Stereoisomeric Peptide Libraries and Peptidomimetics for Designing Selective Inhibitors of the αvβ3 Integrin for a New Cancer Therapy. Angew. Chem., Int. Ed. 1997, 36, 1374-1389.
32. (h) Duggan, M. E.; Duong, L. T.; Fisher, J. E.; Hamill, T. G.; Hoffman, W. F.; Huff, J. R.; Ihle, N. C.; Leu, C.-T.; Nagy, R. M.; Perkins, J. J.; Rodan, S. B.; Wesolowski, G. A.; Whitman, D. B.; Zartman, A. E.; Rodan, G. A.; Hartman, G. D. Nonpeptide αvβ3 Antagonists. 1. Transformation of a Potent, Integrin-Selective αIIbβ3 Antagonist into a Potent αvβ3 Antagonist. J. Med. Chem. 2000, 43, 3736-3745.
33. (a) Haubner, R.; Schmitt, W.; Hölzemann, G.; Goodman, S. L.; Jonczyk, A.; Kessler, H. Cyclic RGD Peptides Containing β-Turn Mimetics. J. Am. Chem. Soc. 1996, 118, 7881-7891.
34. (b) Pitts, W. J.; Wityak, J.; Smallheer, J. M.; Tobin, A. E.; Jetter, J. W.; Buynitsky, J. S.; Harlow, P. P.; Solomon, K. A.; Corjay, M. H.; Mousa, S. A.; Wexler, R. R.; Jadhav, P. K. Isoxazolines as Potent Antagonists of the Integrin αvβ3. J. Med. Chem. 2000, 43, 27-40.
35. (c) Batt, D. G.; Petraitis, J. J.; Houghton, G. C.; Modi, D. P.; Cain, G. A.; Coryay, M. H.; Mousa, S. A.; Bouchard, P. J.; Forsythe, M. S.; Harlow, P. P.; Barbera, F. A.; Spitz, S. M.; Wexler, R. R.; Jadav, P. K.; Disubstituted indazoles as potent antagonists of the integrin αvβ3. J. Med. Chem. 2000, 43, 41-58.
36. (d) Belvisi, L.; Bernardi, A.; Checchia, A.; Manzoni, L.; Potenza, D.; Scolastico, C.; Castorina, M.; Cupelli, A.; Giannini, G.; Carminati, P.; Pisano, C. Potent integrin antagonists from a small library of RGD-including cyclic pseudopeptides. Org. Lett. 2001, 3, 1001-1004.
37. (e) Hölzemann, G. Recent advances in avb3 integrin inhibitors. Drugs 2001, 4, 72-81.
38. (f) Sulyok, G. A. G.; Gibson, C.; Goodman, S. L.; Hölzemann, G.; Wiesner, M.; Kessler, H. Solid-Phase Synthesis of a Nonpeptidic RGD Mimetic Library: New Selective αvβ3 Integrin Antagonists. J. Med. Chem. 2001, 44, 1938-1950.
39. (g) Goodman, S. L.; Hölzemann, G.; Sulyok, G. A. G.; Kessler, H. Nanomolar Small Molecule Inhibitors for αvβ6, αvβ5, and αvβ3 Integrins. J. Med. Chem. 2002, 45, 1045-1051.
40. Lin, E. C. K.; Ratnikov, B. I.; Tsai, P. M.; Carron, C. P.; Myers, D. M.; Barbas, C. F., III; Smith, J. W. Identification of a region in the integrin β3 subunit that conferes ligand binding specificity. J. Biol. Chem. 1997, 38, 23912-23920.
41. Takagi, J.; Tetsuji, K.; Meredith, J.; Puzon-McLaughlin, W.; Takada, Y.; Changing ligand specificities of αvβ1 and αvβ3 integrins by swapping a short diverse sequence of a β subunit. J. Biol. Chem. 1997, 32, 19794-19800.
42. Xiong, J.-P.; Stehle, T.; Zhang, R.; Joachimiak, A.; Frech, M.; Goodman, S. L.; Arnaout, M. A. Crystal Structure of the Extracellular Segment of Integrin αvβ3 in Complex with an Arg-Gly-Asp Ligand. Science 2002, 296, 151-155.
43. Xiong, J.-P.; Stehle, T.; Diefenbach, B.; Zhang, R.; Dunker, R.; Scott, D. L.; Joachimiak, A.; Goodman, S. L.; Arnaout, M. A. Crystal Structure of the Extracellular Segment of Integrin αvβ3. Science 2001, 294, 339-345.
44. (a) Liddington, R. C.; and Ginsberg, M. H. Integrin activation takes shape. J. Cell Biol. 2002, 158, 833-839.
45. (b) Takagi, J.; and Springer, T. A. Integrin activation and structural rearrangement. Immunol. Rev. 2002, 186, 141-163.
46. (c) Arnaout, M. A. Integrin structure: new twists and turns in dynamic cell adhesion. Immunol. Rev. 2002 186, 125-140.
47. (c) Humphries, M. J.; Symonds, E. J. H.; Mould A. P. Mapping functional residues onto integrin crystal structures. Curr. Opin. Struct. Biol. 2003, 13, 236-243.
48. (a) Springer, T. A. Predicted and experimental structures of integrins and β-propellers. Curr. Opin. Struct. Biol. 2002, 12, 802-813.
49. (b) Vinogradova, O.; Velyvis, A.; Velyviene, A.; Hu, B.; Haas, T. A.; Plow, E. F.; Qin, J. A structural mechanism of integrin αIIbβ3 "inside-out" activation as regulated by its cytoplasmic face. Cell 2002, 110, 587-597.
50. (c) Gottschalk, K.-E.; Adams, P. D.; Brunger, A. T.; Kessler, H. Transmembrane signal transduction of the αIIbβ3 integrin. Protein Sci. 2002, 11, 1800-1812.
51. (d) Adair, B. D.; Yeager, M. Three-dimensional model of the human platelet integrin αIIbβ3 based on electron cryomicroscopy and X-ray crystallography. PNAS, 2002, 99, 14059-14064.
52. (e) Takagi, J.; Strokovich, K.; Springer, T. A.; Walz, T. Structure of integrin α5β1 in complex with fibronectin. EMBO J. 2003, 22, 4607-4615.
53. (f) Gottschalk, K.-E.; Kessler, H. Evidence for Hetero-Association of Transmembrane helices of Integrins. FEBS Lett. 2004, 557, 253-258.
54. (a) Gottschalk, K.-E.; Günther, R.; Kessler, H. A Three-State Mechanism of Integrin Activation and Signal Transduction for Integrin αvβ3. ChemBioChem 2002, 3, 470-473.
55. (b) Gottschalk, K.-E.; Kessler, H. The Structures of Integrins and Integrin-Ligand Complexes: Implications for Drug Design and Signal Transduction. Angew. Chem., Int. Ed. 2002, 41, 3767-3774.
56. (c) Marinelli, L.; Lavecchia, A.; Gottschalk, K. E.; Novellino, E.; Kessler, H. Docking studies on αvβ3 Integrin Ligands: Pharmacophore Refinement and Implication for Drug Design. J. Med. Chem. 2003, 46, 4393-4404.
57. (a) You, T. J.; Maxwell, D. S.; Kogan, T. P.; Chen, Q.; Li, J.; Kassir, J.; Holland, G. W.; Dixon, R. A. F. A 3D Structure Model of Integrin α4β1 Complex: Construction of a Homology Model of β1 and Ligand Binding Analysis. Biophys J. 2002, 82, 447-457.
58. 3 Integrin. J. Med. Chem. 2002, 45, 5640-5648.
59. (c) Feuston, B. P.; Culberson, J. C.; Hartman, G. D. Molecular Model of the αIIbβ3 Integrin. J. Med. Chem. 2003, 46, 5316-5325.
60. Plow, E. F.; Haas, T. A.; Zhang, L.; Loftus, J.; Smith J. W. Ligand binding to integrins. J. Biol. Chem. 2000, 275, 21785-8.
61. (a) Masumoto, A.; Hemler, M. E. Mutation of putative divalent cation sites in the a4 subunit of the integrin VLA-4: Distinct effects on adhesion to CS1/fibronectin, VCAM-1, and invasin. J Cell Biol 1993, 123, 245-53.
62. (b) Wilcox, D. A.; Paddock, C. M.; Lyman, S.; Gill, J. C.; Newman, P. J. Glanzmann thrombasthenia resulting from a single amino acid substitution between the second and third calcium-binding domains of GPIIb. Role of the GPIIb amino terminus in integrin subunit association. J. Clin. Invest. 1995, 95, 1553-60.
63. (c) Mitchell, W. B.; Li, J.; Singh, F.; Michelson, A. D.; Bussel, J.; Coller, B. S.; French, D. L. Two novel mutations in the {alpha}IIb calcium-binding domains identify hydrophobic regions essential for {alpha}IIb-{beta}3 biogenesis. Blood 2003, 101, 2268-76.
64. Takagi, J.; DeBottis, D. P.; Erickson, H. P.; Springer, T. A. The role of the specificity-determining loop of integrin β subunit I-like domain in autonomous expression, association with the α subunit, and ligand binding. Biochemistry 2002, 41, 4339-4347.
65. Miller, W. H.; Keenan, R. M.; Willette, R. N.; Lark, M. W. Identification and in vivo efficacy of small-molecule antagonist of integrin αvβ3 (the vitronectin receptor). Ther. Focus. 2000, 5, 397-408.
66. Arnaout, M. A.; Goodman, S. L.; Xiong, J. P. Coming to grips with integrin binding to ligands. Curr. Opin. Cell. Biol. 2002, 14, 641-651.
67. Yamanouchi, J.; Hato, T.; Tamura, T.; Fujita, S. Identification of critical residues for ligand binding in the integrin beta3 I-domain by site-directed mutagenesis. Thromb. Haemost. 2002, 87, 756-762.
68. Yahalom, D.; Wittelsberger, A.; Mierke, D. F.; Rosenblatt, M.; Alexander, J. M.; Chorev, M. Identification of the Principal Binding Site for RGD-Containing Ligands in the αvβ3 Integrin: A Photoaffinity Cross-Linking Study. Biochemistry 2002, 41, 8321-8331.
69. Honda, S.; Tomiyama, Y.; Pampori, N.; Kashiwagi, H.; Kiyoi, T. Kosugi, S.; Tadokoro, S.; Kurata, Y.; Shattil, S. J.; Matsuzawa, Y. Ligand binding to integrin αvβ3 requires tyrosine 178 in the αv subunit. Blood 2001, 97, 175-182.
70. (a) Metzger, T. G.; Paterlini, M. G., Portoghese, P. S.; Ferguson, D. M. Application of the message-address concept to the docking of naltrexone and selective naltrexone-derived opioid antagonists into opioid receptors models. Neurochem. Res. 1996, 21, 1287-1294.
71. (b) Simpson, M. M.; Ballesteros, J. A.; Chiappa, V.; Chen, J.; Suehiro, M.; Hartman, D. S.; Godel, T.; Snyder, L. A.; Sakmar, T. P.; Javitch, J. A. Dopamine D4/D2 receptor selectivity is determined by a divergent aromatic microdomain contained within the second, third, and seventh membrane-spanning segments. Mol. Pharmacol. 1999, 56,1116-1126.
72. (c) Paterlini, M. G. Structure Modeling of the Chemochine Receptor CCR5: Implications for Ligand Binding and Selectivity.
73. Thompson, J. D.; Higgins, D. G.; Gibson, T. J. Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994, 22, 4673-4680.
74. Sali, A.; Potterton, L.; Yuan, F.; van Vlijmen, H.; Karplus, M. Evaluation of Comparative modeling by MODELLER. Protein 1995, 23, 318-326.
75. Pedretti, A.; Villa, L.; Vistoli, G. VEGA: a Versatile Program to Convert, Handle, and Visualize Molecular Structure on Windows-based PCs. J. Mol. Graph. 2002, 21, 47-49.
76. Accelrys, 2001, San Diego, CA.
77. Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thornton, J. M. PROCHECK: a Program to Check the Stereochemical Quality of Protein Structures. J. Appl. Crystallogr. 1993, 26, 283-291.
78. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662.
79. SYBYL Molecular Modeling System (version 6.8), TRIPOS Assoc., St. Louis, MO.
80. Head, J.; Zerner, M. C. A Broyden-Fletcher-Goldfarb-Shanno Optimization Procedure for Molecular Geometries. Chem. Phys. Lett. 1985, 122, 264-274.
81. Vinter, J. G.; Davis, A.; Saunders: M. R. Strategic Approaches to Drug Design. 1. An Integrated Software Framework for Molecular Modelling. J. Comput.-Aided Mol. Des. 1987, 1, 31-55.
82. Gasteiger, J.; Marsili, M. Iterative partial equalization of orbital electronegativity - a rapid access to atomic charges. Tetrahedron 1980, 36, 3219-3228.
83. Allen, F. H.; Bellard, S.; Brice, M. D.; Cartwright, B. A.; Doubleday: A.; Higgs, H.; Hummelink, T.; Hummelink-Peters, B. G.; Kennard, O.; Motherwell, W. D. S. The Cambridge Crystallographic Data Center: Computer-Based Search, Retrieval, Analysis and Display of Information. Acta Crystallogr. 1979, B35, 2331-2339.
84. (a) Chakravorty, S.; Reynolds, C. H. Improved AMBER torsional parameters for the N-N rotational barrier in diacylhydrazines. J. Mol. Graph. Model. 1999, 17, 315-324.
85. (b) Günther, R.; Hofmann, H. J. Hydrazino peptides as foldamers: an extension of the β-peptide concept. J. Am. Chem. Soc. 2001, 123, 247-255.